← Eichor
Study identifier: NCT06859801 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy

Condition: Bone Cancer Metastatic  ·  Sponsor: Society of Interventional Oncology

PhaseN/A
Planned participants120
Who can joinAll sexes, 21 Years to no upper limit
Healthy volunteersNo

About this study

The objective of this study is to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilization, etc.) in patients treated with both percutaneous ablation and palliative radiation therapy (RT).

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (7)

University of California San Diego Moores Cancer CenterSan Diego, California, United StatesRecruiting
Baptist Health Medical GroupMiami, Florida, United StatesRecruiting
Emory University HospitalAtlanta, Georgia, United StatesRecruiting
Northside HospitalAtlanta, Georgia, United StatesRecruiting
Mayo ClinicRochester, Minnesota, United StatesRecruiting
Washington UniversitySt Louis, Missouri, United StatesRecruiting
Medical College of WisconsinMilwaukee, Wisconsin, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06859801